The Consumer Discretionary Select Sector SPDR Fund (XLY)
- Previous Close
196.89 - Open
200.51 - Bid 200.69 x 1100
- Ask 200.70 x 800
- Day's Range
199.91 - 202.14 - 52 Week Range
158.15 - 203.08 - Volume
2,696,274 - Avg. Volume
2,844,792 - Net Assets 19.48B
- NAV 196.98
- PE Ratio (TTM) 31.30
- Yield 0.75%
- YTD Daily Total Return 10.81%
- Beta (5Y Monthly) 1.29
- Expense Ratio (net) 0.09%
The Advisor employs a replication strategy. The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Discretionary companies by the Global Industry Classification Standard (GICS®). It is non-diversified.
SPDR State Street Global Advisors
Fund Family
Consumer Cyclical
Fund Category
19.48B
Net Assets
1998-12-16
Inception Date
Performance Overview: XLY
View MoreTrailing returns as of 10/31/2024. Category is Consumer Cyclical.
People Also Watch
Holdings: XLY
View MoreTop 10 Holdings (69.39% of Total Assets)
Sector Weightings
Recent News: XLY
View MoreResearch Reports: XLY
View MoreBiogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBiogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBUY on regulatory advancements and higher guidance
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.
RatingPrice TargetU.S. stock indices are mostly in the red today, with investors perhaps
U.S. stock indices are mostly in the red today, with investors perhaps experiencing a little 'green exhaustion' after the solid gains booked of late. Also of note, the meaningful news starts to hit the tape tomorrow with the release of the Fed minutes, so getting a little defensive in case the minutes include unwanted news is also defensible.